Clinical Trial Update: Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+ [Phase 2]

View source ↗

Summary

This clinical trial update reports a Phase 2 study evaluating zanubrutinib in patients with diffuse large B-cell lymphoma who have MYD88 or NOTCH1 mutations or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Virginia Commonwealth University | Conditions: Diffuse Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma | Phase 2 | Status: RECRUITING